新闻动态 News
查看更多 >>
-
2026-03-25近日,以“因聚而升 融智有为”为主题的华为中国合作伙伴大会2026在深圳圆满落幕。望石智慧作为其国内AI驱动医药创新领域的核心技术伙伴受邀参会,并在智能制造医药行业论坛发表演讲。会议期间,望石智慧、华为、华鲲振宇三方达成战略级生态合作,正式发布“AI药研联合解决方案”,旨在通过自主创新算力底座与全链条数智化解决方案,构建中国医药行业“第二科技平面”,推动中国医药产业迈向高质量发展新阶段。 此外,在数智医药专属展区中,望石智慧全方位展现自研AI制药领域医药技术创新成果,现场交流洽谈氛围热烈,吸引众多行业合作伙伴驻足,这既彰显了望石在数智医药领域的技术引领与市场认可,更是其在深化生态合作、赋能医药创新的生动实践。 强强联合,AI辅助药物研发融合范式重磅落地! 当前,医药产业正加速迈向数智化升级,传统药物研发周期长、成本高、算力对外依赖等痛点日益突出。将自主可控的算力支撑与成熟的AI药物研发技术平台深度融合,构建协同共生的数智医药产业生态,已成为行业破局升级的...
-
2026-03-193月18日,2026新时代品牌发展论坛暨福布斯中国行业发展领创者评选荣耀盛典在上海圆满举办。依托行业领先的技术壁垒、可规模化的落地实力,望石智慧获评“2026福布斯中国行业发展领军企业”,成为此次获奖名单中唯一的AI制药企业。该荣誉不仅是对望石智慧技术实力与产业价值的权威认可,更标志着望石智慧作为人工智能与生物医药融合创新的标杆力量,正式跻身行业主流视野。 同期获评的还包括优必选科技、海天味业、泰德医药、昆仑新能源等行业细分龙头,覆盖AI、大消费、医疗健康、新能源等关键赛道,入选企业均为各领域具备可持续发展能力的标杆力量。 本次评选由福布斯中国与全球知名增长咨询机构弗若斯特沙利文联合发起,以国家战略响应、创新表现、商业成长力、可持续发展能力、行业影响力五大核心维度为评审标准,重点考察参选主体在行业赋能、商业运营与创新实践中的表现。 望石智慧始终致力于人工智能与生物医药的深度融合,积极响应国家创新发展战略,以科技创新助力医药产业高质量升级,用实际成果践行科技赋能实体经济的发展方向。 通过多轮数据...
-
2026-03-10近日,北京市科学技术委员会、中关村科技园区管理委员会正式公布2025年北京市重点实验室名单。由北京大学与望石智慧联合申报的“智慧药物研发北京市重点实验室”成功获批(证书号:BZ-2025-084)。该实验室是北京大学医学部首个以“智慧药物研发”命名的市级重点实验室,标志着双方在人工智能与医药交叉融合领域迈出关键一步。 该实验室是北京大学医学部在智慧药物研发方向的核心科研平台,覆盖医学部整体科研体系,聚焦AI赋能药物创新的前沿方向。此次获批,是权威机构对望石智慧科研创新能力、技术研发实力与产学研协同创新能力的高度认可,意味着望石智慧作为共建单位,服务于北京大学医学乃至北京地区在智慧药物研发领域的战略需求,助力加速AI制药技术与生物医药研发的深度融合。 北京市重点实验室认定标准严格,涵盖科研条件、研究方向、团队建设、成果转化等多个维度。此次获批,充分证明该实验室在智慧药物研发方向具备了领先的科研攻关能力、扎实的技术积累和完善的产学研协同机制,彰显了望石智慧在智慧药物研发领域深厚的技术积淀...
-
2025-11-192025年11月19日,北京望石智慧科技有限公司宣布与深圳微芯生物()科技股份有限公司(股票代码:688321.SH)正式启动基于 MolVado AI 3D 分子生成与小分子药物设计平台 的合作。根据合作安排,望石智慧将向微芯生物提供一套由分子生成模型、系列AIDD()计算工具和计算底座组成的工程化 AI 解决方案,支持其在小分子药物研发阶段的探索与优化工作。 作为中国原创新药领域的先行者,微芯生物汇聚相关领域具有资深经验的顶尖科学家团队,应用基于AI辅助设计+化学基因组学的整合式技术平台,成功开发出西达本胺(肿瘤)及西格列他钠(2型糖尿病)两款全球首创(First-in-class)且同类最优(Best-in-class)的原创新药,多个适应症在全球上市销售,且在恶性肿瘤、代谢性疾病、自身免疫性疾病、神经退行性疾病等领域布局了多个具有差异化优势和全球竞争力的研发项目。本次合作的启动,是双方共同在数字化研发工具链上的又一次战略性探索。 微芯生物首席科学官潘德思博士表示: “微芯生物始终坚持高质量创新的研发理念,不断探索可以提升药物发现效率的技...
-
2025-11-12望石智慧: 感谢天津市滨海新区科技局、天津国际生物医药联合研究院的精心组织与邀请,以及各位参会同仁的精彩分享与宝贵建议!望石智慧深耕 AI 分子生成领域多年,在模型构建、技术迭代与落地运营方面积累了扎实的实践经验与成熟的方法论。 诚挚欢迎行业同仁与我们建立深度联系,围绕个性化模型定制、创新需求共创等方向深化合作,携手破解研发痛点,共推 AI 赋能生物医药产业的创新发展! 10月30日下午,天津经开区科技创新局联合天津国际生物医药联合研究院,共同举办“人工智能赋能小分子药物研发”交流座谈会。来自北京望石智慧科技有限公司的核心团队与区内12家生物医药创新企业代表齐聚一堂,共绘AI驱动药物研发的新蓝图。 会上,望石智慧团队系统展示了AI分子生成、活性预测及管线研发增速降本等核心技术,分享了与国内外药企合作案例;瀚盟测试、睿创康泰、法尔玛制药、丹娜生物、全和诚生物以及辰欣药业等与会企业围绕数据共享、算法适配、临床转化等痛点展开深入对接交流。 下一步,经开区将聚焦协同创新和科技成果转化,加...
-
2025-11-12关于AI for Life Science,一份重磅报告刚刚出炉! 10月30日,弗若斯特沙利文发布《2025中国AI4LS行业发展蓝皮书》,全景式、深层次地展现了AI for Life Science的发展历程、驱动因素、场景应用与未来趋势。 蓝皮书指出,在经历了经验科学、理论科学、计算科学、数据密集型科学的前四大范式之后,在AI的加持下,当前的科学研究正向第五范式——以AI为核心的智能化科研方向进化。 截至2024年,中国AI4S市场规模已达47亿元,涵盖药物研发、合成生物学、基因测序、材料开发及电池与储能等核心领域,从中长期发展来看,AI4S市场规模有望突破千亿元体量。 其中,生命科学凭借深厚的数据基础、高复杂问题与广阔的应用前景,正逐步成为AI4S最理想的应用场景之一。 蓝皮书指出,不同类型企业围绕平台构建、模型驱动与落地能力展开多元探索,代表性公司通过差异化技术路径和应用模式,正在推动AI从工具向赋能主体的跃迁。 在药物研发场景下,成立于2018年的望石智慧,入选本次蓝皮书的代表性公司。 凭借人工智能药物研发底层...
学术进展 Academic Progress
查看更多 >>
-
2024-07-11Weiqiang Fu, Yujie Mo, Yi Xiao, Chang Liu, Feng Zhou, Yang Wang, Jielong Zhou*, Yingsheng J. Zhang* June 3, 2024 DOI: https://doi.org/10.1021/acs.jctc.3c01181 Abstract: Exclusively prioritizing the precision of energy prediction frequently proves inadequate in satisfying multifaceted requirements. A heightened focus is warranted on assessing the rationality of potential energy curves predicted by machine learning-based force fields (MLFFs), alongside evaluating the pragmatic utility of these MLFFs. This study introduces SWANI, an optimized neural network potential stemming from the ANI framework. Through the incorporation of supplementary physical constraints, SWANI aligns more cohesively with chemical expectations, yielding rational potential energy profiles. It also exhibits superior predictive precision compared with that of the A...
-
2024-07-05Feng Zhou, Haolin Du, Yang Wang, Weiqiang Fu, Bingchen Zhao, Jielong Zhou*, Yingsheng J. Zhang. June 5, 2024 DOI: https://doi.org/10.1021/acsmedchemlett.4c00047 Abstract: We employ a combination of accelerated molecular dynamics and machine learning to unravel how the dynamic characteristics of CBL-B and C–CBL confer their binding affinity and selectivity for ligands from subtle structural disparities within their binding pockets and dissociation pathways. Our predictive model of dissociation rate constants (koff) demonstrates a moderate correlation between predicted koff and experimental IC50 values, which is consistent with experimental koff and τ-random accelerated molecular dynamics (τRAMD) results. By employing a linear regression of dissociation trajectories, we identified key amino acids in binding pockets and along the dissociati...
-
2024-01-15Wei Feng, Lvwei Wang, Zaiyun Lin, Yanhao Zhu, Han Wang, Jianqiang Dong, Rong Bai, Huting Wang, Jielong Zhou, Wei Peng, Bo Huang & Wenbiao Zhou 15 January 2024 DOI: https://doi.org/10.1038/s42256-023-00775-6 Abstract: Generative models for molecules based on sequential line notation (for example, the simplified molecular-input line-entry system) or graph representation have attracted an increasing interest in the field of structure-based drug design, but they struggle to capture important three-dimensional (3D) spatial interactions and often produce undesirable molecular structures. To address these challenges, we introduce Lingo3DMol, a pocket-based 3D molecule generation method that combines language models and geometric deep learning technology. A new molecular representation, the fragment-based simplified molecular-input lin...
-
2023-12-11Di Wu, Qihao Chen, Zhuoya Yu, Bo Huang, Jun Zhao, Yuhang Wang, Jiawei Su, Feng Zhou, Rui Yan, Na Li, Yan Zhao & Daohua Jian. 11 December 2023 DOI: https://doi.org/10.1038/s41586-023-06926-4 Abstract: Vesicular monoamine transporter 2 (VMAT2) accumulates monoamines in presynaptic vesicles for storage and exocytotic release, and has a vital role in monoaminergic neurotransmission1,2,3. Dysfunction of monoaminergic systems causes many neurological and psychiatric disorders, including Parkinson’s disease, hyperkinetic movement disorders and depression4,5,6. Suppressing VMAT2 with reserpine and tetrabenazine alleviates symptoms of hypertension and Huntington’s disease7,8, respectively. Here we describe cryo-electron microscopy structures of human VMAT2 complexed with serotonin and three clinical drugs at 3.5–2.8 &Ari...
-
2023-12-05Bo Qiang, Yiran Zhou, Yuheng Ding, Ningfeng Liu, Song Song, Liangren Zhang, Bo Huang & Zhenming Liu. 05 December 2023 DOI: https://doi.org/10.1038/s42256-023-00764-9 Abstract: Chemical reactions are the fundamental building blocks of drug design and organic chemistry research. In recent years, there has been a growing need for a large-scale deep-learning framework that can efficiently capture the basic rules of chemical reactions. In this paper, we have proposed a unified framework that addresses both the reaction-representation learning and molecule generation tasks, which allows for a more holistic approach. Inspired by the organic chemistry mechanism, we develop a new pretraining framework that enables us to incorporate inductive biases into the model. Our framework achieves state-of-the-art results in performance of challenging downstream tasks. By poss...
-
2023-11-21Lanying Wei, Yucui Xin,Mengchen Pu,Yingsheng Zhang. 17 November 2023. DOI: https://doi.org/10.26508/lsa.202302253 Abstract: To effectively understand the underlying mechanisms of disease and inform the development of personalized therapies, it is critical to harness the power of differential co-expression (DCE) network analysis. Despite the promise of DCE network analysis in precision medicine, current approaches have a major limitation: they measure an average differential network across multiple samples, which means the specific etiology of individual patients is often overlooked. To address this, we present Cosinet, a DCE-based single-sample network rewiring degree quantification tool. By analyzing two breast cancer datasets, we demonstrate that Cosinet can identify important differences in gene co-expression patterns between individual patients and g...



